Heartflow (NASDAQ:HTFL) Raised to “Hold” at UBS Group

Heartflow (NASDAQ:HTFL) was upgraded by analysts at UBS Group to a “hold” rating in a research note issued to investors on Wednesday, Zacks reports.

A number of other analysts also recently issued reports on HTFL. Canaccord Genuity Group increased their target price on shares of Heartflow from $37.00 to $45.00 and gave the stock a “buy” rating in a research report on Friday, August 14th. Freedom Capital raised shares of Heartflow to a “strong-buy” rating in a research note on Tuesday, June 30th. Robert W. Baird set a $45.00 price target on shares of Heartflow in a research report on Friday, August 14th. Weiss Ratings upgraded Heartflow from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 7th. Finally, Wells Fargo & Company raised their price objective on Heartflow from $37.00 to $39.00 and gave the company an “overweight” rating in a research report on Friday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $44.88.

Heartflow Stock Up 9.7%

Shares of NASDAQ HTFL opened at $49.88 on Wednesday. The stock has a market capitalization of $4.34 billion and a PE ratio of -27.26. The firm has a fifty day moving average of $35.52 and a 200-day moving average of $30.78. Heartflow has a 52-week low of $20.13 and a 52-week high of $51.78.

Heartflow (NASDAQ:HTFL) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.15. The firm had revenue of $64.08 million during the quarter. Heartflow had a negative return on equity of 23.52% and a negative net margin of 55.82%.Heartflow’s revenue was up 47.7% compared to the same quarter last year. Equities research analysts expect that Heartflow will post -0.75 EPS for the current fiscal year.

Insider Transactions at Heartflow

In other Heartflow news, CEO John Farquhar sold 38,900 shares of the business’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $35.00, for a total value of $1,361,500.00. Following the transaction, the chief executive officer owned 457,935 shares in the company, valued at $16,027,725. The trade was a 7.83% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Campbell Rogers sold 9,219 shares of the firm’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $41.23, for a total value of $380,099.37. Following the sale, the insider owned 86,459 shares of the company’s stock, valued at $3,564,704.57. This represents a 9.64% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 208,765 shares of company stock valued at $8,444,106. Corporate insiders own 7.70% of the company’s stock.

Institutional Trading of Heartflow

A number of hedge funds have recently made changes to their positions in HTFL. Engineers Gate Manager LP bought a new stake in shares of Heartflow in the 2nd quarter worth about $590,000. Integrated Wealth Concepts LLC acquired a new stake in Heartflow during the second quarter valued at approximately $53,000. Squarepoint Ops LLC lifted its holdings in Heartflow by 72.0% during the 2nd quarter. Squarepoint Ops LLC now owns 87,052 shares of the company’s stock worth $2,554,000 after buying an additional 36,441 shares during the last quarter. Arizona State Retirement System acquired a new stake in shares of Heartflow during the 2nd quarter valued at approximately $312,000. Finally, Allianz Asset Management GmbH bought a new position in Heartflow during the second quarter worth $1,557,000.

Heartflow Company Profile

Heartflow, Inc is a medical technology company that develops artificial intelligence and imaging solutions for the diagnosis and management of coronary artery disease. Its platform analyzes data from coronary computed tomography angiography (CCTA) scans to create personalized, three-dimensional models of a patient’s coronary arteries.

The company’s primary offering, Heartflow Analysis, is designed to provide noninvasive estimates of fractional flow reserve derived from computed tomography (FFR^CT).